Antibody Fc-binding profiles and ACE2 affinity to SARS-CoV-2 RBD variants

• Published in: Medical microbiology and immunology 2023-08, Vol.212 (4), p.291-305
• Main Authors: Haycroft, Ebene R., Davis, Samantha K., Ramanathan, Pradhipa, Lopez, Ester, Purcell, Ruth A., Tan, Li Lynn, Pymm, Phillip, Wines, Bruce D., Hogarth, P. Mark, Wheatley, Adam K., Juno, Jennifer A., Redmond, Samuel J., Gherardin, Nicholas A., Godfrey, Dale I., Tham, Wai-Hong, Selva, Kevin John, Kent, Stephen J., Chung, Amy W.
• Format: Article
• Language: English
• Subjects: ACE2; Affinity; Angiotensin-converting enzyme 2; Antibodies; Biomedical and Life Sciences; Biomedicine; COVID-19; Immunoglobulin G; Immunology; Medical Microbiology; Mutation; Mutation hot spots; Original Investigation; Point mutation; Public health; Severe acute respiratory syndrome coronavirus 2; Virology
• ISSN: 0300-8584; 1432-1831
• DOI: 10.1007/s00430-023-00773-w

Emerging SARS-CoV-2 variants, notably Omicron, continue to remain a formidable challenge to worldwide public health. The SARS-CoV-2 receptor-binding domain (RBD) is a hotspot for mutations, reflecting its critical role at the ACE2 interface during viral entry. Here, we comprehensively investigated the impact of RBD mutations, including 5 variants of concern (VOC) or interest—including Omicron (BA.2)—and 33 common point mutations, both on IgG recognition and ACE2-binding inhibition, as well as FcγRIIa- and FcγRIIIa-binding antibodies, in plasma from two-dose BNT162b2-vaccine recipients and mild-COVID-19 convalescent subjects obtained during the first wave using a custom-designed bead-based 39-plex array. IgG-recognition and FcγR-binding antibodies were decreased against the RBD of Beta and Omicron, as well as point mutation G446S, found in several Omicron sub-variants as compared to wild type. Notably, while there was a profound decrease in ACE2 inhibition against Omicron, FcγR-binding antibodies were less affected, suggesting that Fc functional antibody responses may be better retained against the RBD of Omicron in comparison to neutralization. Furthermore, while measurement of RBD–ACE2-binding affinity via biolayer interferometry showed that all VOC RBDs have enhanced affinity to human ACE2, we demonstrate that human ACE2 polymorphisms, E35K (rs1348114695) has reduced affinity to VOCs, while K26R (rs4646116) and S19P (rs73635825) have increased binding kinetics to the RBD of VOCs, potentially affecting virus–host interaction and, thereby, host susceptibility. Collectively, our findings provide in-depth coverage of the impact of RBD mutations on key facets of host–virus interactions.